ACC Urges Lawmakers to Support Bill to Avoid Medicare Cuts Threatening Patient Access to Care

The American College of Cardiology is urging members of Congress to co-sponsor and pass the Preserving Seniors’ Access to Physicians Act of 2023 (H.R. 6683), which would eliminate the impending 3.37% cut to the Medicare Physician Fee Schedules set to take effect on Jan. 1, 2024.

“We have once again arrived at American clinicians’ annual holiday tradition: urging Congress to not allow cuts to Medicare services that exacerbate financial uncertainty for practices, further threaten patient access to care, and disproportionately impact America’s rural and senior populations,” said American College of Cardiology President B. Hadley Wilson, MD, FACC. “For decades we have spent December looking for a quick fix to a problem that requires significant reforms. We must seek and establish sustainable payment practices that allow clinicians to continue providing access to high-quality care. While addressing this upcoming cut is critical, it is a short-term adjustment that will not create a long-term solution. It is necessary to protect patients now while we work together on lasting reform.”

A full fix to the 3.37% cut is necessary to combat the lack of inflationary update despite clinicians and practices facing significant inflationary cost pressure. Physicians are the only providers that do not receive an automatic inflationary update within Medicare. Medicare physician payments have dropped by 26% in the last 20 years, while practice expenses have risen by 47% over the same period. Congress must act now to avert this crisis to maintain stable, consistent access to care for some of America’s most vulnerable patients.

The ACC is leading the charge to transform cardiovascular care delivery. Tasked with advocating for cardiovascular patients and providing a professional home for the entire cardiovascular team, the ACC is committed to developing and advancing solutions that will optimize the delivery of cardiovascular care, increase access to care and improve patient outcomes and health. However, significant reforms are required within the current Medicare system to achieve the ACC’s vision. Learn more about the ACC’s Vision for Optimal Cardiovascular Care at ACC.org/OptimizeCVCare.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version